Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Going for broke: how universities can deliver on their economic potential

7 August 2012

By Stephen Caddick, Vice-Provost (Enterprise) at UCL
The UK needs an economic game changer and we are incredibly fortunate to have a platform from which we can launch it – our universities.

Read the full article at www.guardian.co.uk